Ieq Capital LLC Purchases New Holdings in Myriad Genetics, Inc. $MYGN

Posted by Stanley Muller on Aug 27th, 2026

Ieq Capital LLC purchased a new stake in Myriad Genetics, Inc. (NASDAQ:MYGN – Free Report) in the second quarter, HoldingsChannel.com reports. The institutional investor purchased 254,869 shares of the company’s stock, valued at approximately $1,455,000.

Other institutional investors have also recently made changes to their positions in the company. Orbimed Advisors LLC bought a new position in shares of Myriad Genetics in the first quarter valued at $562,500,000. Vanguard Group Inc. raised its position in Myriad Genetics by 4.3% during the fourth quarter. Vanguard Group Inc. now owns 8,225,371 shares of the company’s stock worth $50,586,000 after acquiring an additional 342,856 shares in the last quarter. Y Intercept Hong Kong Ltd raised its position in Myriad Genetics by 83.3% during the first quarter. Y Intercept Hong Kong Ltd now owns 654,224 shares of the company’s stock worth $2,944,000 after acquiring an additional 297,331 shares in the last quarter. Assenagon Asset Management S.A. lifted its stake in Myriad Genetics by 23.9% in the first quarter. Assenagon Asset Management S.A. now owns 1,446,961 shares of the company’s stock valued at $6,511,000 after acquiring an additional 279,227 shares during the last quarter. Finally, UBS Group AG grew its position in shares of Myriad Genetics by 29.8% in the 4th quarter. UBS Group AG now owns 639,691 shares of the company’s stock valued at $3,934,000 after acquiring an additional 147,045 shares during the period. Institutional investors and hedge funds own 99.02% of the company’s stock.

Myriad Genetics Stock Down 2.2%

Shares of MYGN opened at $3.12 on Thursday. The company has a current ratio of 2.21, a quick ratio of 1.98 and a debt-to-equity ratio of 0.40. Myriad Genetics, Inc. has a 12 month low of $2.74 and a 12 month high of $8.59. The firm’s 50 day moving average is $4.68 and its 200-day moving average is $4.59. The stock has a market capitalization of $298.43 million, a PE ratio of -2.62 and a beta of 1.69.

Myriad Genetics (NASDAQ:MYGN – Get Free Report) last issued its quarterly earnings results on Thursday, July 30th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.06) by ($0.19). The company had revenue of $190.70 million during the quarter, compared to the consensus estimate of $206.03 million. Myriad Genetics had a negative net margin of 13.96% and a negative return on equity of 16.09%. The company’s quarterly revenue was down 10.5% on a year-over-year basis. During the same quarter last year, the firm posted $0.05 earnings per share. Equities research analysts forecast that Myriad Genetics, Inc. will post -0.99 EPS for the current year.

Insiders Place Their Bets

In other news, Director Rashmi Kumar sold 15,000 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The shares were sold at an average price of $4.46, for a total transaction of $66,900.00. Following the completion of the sale, the director owned 171,889 shares of the company’s stock, valued at approximately $766,624.94. This represents a 8.03% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 1.90% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

MYGN has been the topic of several recent analyst reports. TD Cowen lowered their price objective on shares of Myriad Genetics from $6.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, July 31st. Weiss Ratings cut Myriad Genetics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Thursday, July 30th. Wells Fargo & Company lowered their price target on Myriad Genetics from $5.50 to $3.00 and set an “equal weight” rating on the stock in a research report on Monday, August 3rd. Stephens cut their price target on Myriad Genetics from $5.00 to $3.00 and set an “equal weight” rating for the company in a report on Tuesday, August 18th. Finally, Zacks Research cut Myriad Genetics from a “hold” rating to a “strong sell” rating in a report on Tuesday, August 4th. One research analyst has rated the stock with a Buy rating, four have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Reduce” and a consensus target price of $4.90.

Get Our Latest Stock Analysis on MYGN

About Myriad Genetics

(Free Report)

Myriad Genetics (NASDAQ: MYGN) is a molecular diagnostics company that develops and commercializes genetic tests designed to assess an individual’s risk for various hereditary conditions and to guide personalized treatment decisions. The company’s core business centers on predictive medicine, with a focus on hereditary cancer risk assessment through its flagship BRACAnalysis® test for BRCA1 and BRCA2 gene mutations. In addition to oncology, Myriad offers tests in women’s health, neurology and pharmacogenomics to support more informed clinical decision-making.

Among its product offerings are the myRisk® Hereditary Cancer test, which screens for mutations across multiple cancer-related genes, and Prequel®, a non-invasive prenatal test for assessing fetal chromosomal abnormalities.